Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by Pragmatiston Feb 20, 2021 6:09pm
273 Views
Post# 32619873

RE:RE:Shelf Supplement

RE:RE:Shelf Supplement
Hideaway wrote: If they are selling to the public at $6 per share, does this include the warrants? If not, can one purchase the warrants seperately? Hope someone on Board can educate me and, if shares and/or warrants are avaiable how does a small investor participate?TIA.




Hideaway, further to iscfa's post, it appearsfrom the supplement  that the units can boken up to sell as shares and warrants under specific circumstances, so you might be able to pick up warrants on their own. Probaly a small chance, but you  would have to talk to your broker.
 
"The Company has granted to the Underwriters the Over-Allotment Option exercisable, in whole or in part, at the
Underwriters' sole discretion, on or before 5:00 p.m. (EST) on the 30th day following the Closing Date, to offer and
sell up to 877,500 Additional Units, Additional Shares, and/or Additional Warrants that is equal to 15% of the number
of Units sold hereunder at a price equal to the Offering Price (in respect of the Additional Units), at $5.3751, in respect
of the Additional Shares and at $0.6249 per each one-half of one Additional Warrant (or $1.25 per Additional Warrant),
to cover over-allocations, if any, and for market stabilization purposes
<< Previous
Bullboard Posts
Next >>